# Becton, Dickinson and Company

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Becton, Dickinson and Company).

## Overview

Becton, Dickinson and Company (BD) is a U.S.-based medical technology company with roots dating back to 1897 and incorporation in 1906. It develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products used across hospitals, physician offices, laboratories, pharmaceutical companies, and public health settings. BD’s portfolio is built around medication management, patient safety, infection prevention, surgical and interventional care, drug delivery, anesthesiology support, infectious disease diagnosis, and cellular research. The company operates globally and sells through a mix of direct channels and distributors, with a large installed base in healthcare institutions and clinical workflows. BD is also in the middle of a structural shift, with its Life Sciences segment being separated and combined with Waters Corporation, which will change the company’s future segment mix.

## Products & services

• Medication management and drug delivery devices
• Infection prevention and safety-engineered products
• Surgical and interventional procedure devices
• Diagnostic products for infectious disease and cancer
• Laboratory equipment for clinical and research use
• Anesthesiology and patient monitoring solutions
• Cellular research and biosciences tools

- **Medical Essentials** (35%) — Core consumable and device products used in medication delivery, safety, and routine care workflows.
- **Connected Care** (15%) — Patient monitoring, medication management, and workflow solutions that support care delivery.
- **BioPharma Systems** (10%) — Drug delivery and related systems sold to pharmaceutical and healthcare customers.
- **Interventional** (20%) — Devices used in surgical, urology, and critical care procedures.
- **Life Sciences** (20%) — Biosciences and diagnostic products for laboratories, researchers, and testing workflows.

- Medication management and drug delivery devices
- Infection prevention and safety-engineered products
- Surgical and interventional procedure devices
- Diagnostic products for infectious disease and cancer
- Laboratory equipment for clinical and research use
- Anesthesiology and patient monitoring solutions
- Cellular research and biosciences tools

## Customers

BD sells primarily to healthcare institutions and professionals that need high-volume, regulated products embedded in daily clinical workflows. Hospitals and clinics are the core customer base for medication delivery, infection prevention, monitoring, and interventional devices, while physicians’ offices and ambulatory settings buy selected consumables and procedure-related products. Clinical laboratories, life science researchers, and pharmaceutical companies purchase diagnostic and research tools, often for specialized testing, discovery, or manufacturing workflows. BD also serves consumers and retail pharmacies in certain product lines, and public health agencies for prevention and diagnostic use cases. Demand is influenced by procedure volumes, healthcare budgets, reimbursement conditions, and government research funding, which makes the customer mix sensitive to macro and policy changes.

- **Hospitals and clinics** (primary) — Buy medication management, infection prevention, monitoring, and interventional products to support routine inpatient and outpatient care.
- **Clinical laboratories** (primary) — Buy diagnostic instruments, reagents, and lab equipment for infectious disease and other testing workflows.
- **Physicians’ offices and ambulatory care** (secondary) — Buy selected devices and consumables used in office-based procedures and drug delivery.
- **Pharmaceutical companies** (secondary) — Buy drug delivery systems and related technologies that support manufacturing, administration, and research.
- **Life science researchers** (secondary) — Buy biosciences and laboratory products for research, discovery, and cellular applications.
- **Public health agencies and consumers** (emerging) — Buy prevention, diagnostic, and retail-oriented products, often tied to public health programs or home use.

- Hospitals and clinics buying consumables and procedure devices for daily care
- Physicians’ offices purchasing medication delivery and diagnostic products
- Clinical laboratories using diagnostic systems and testing consumables
- Life science researchers buying biosciences tools and lab equipment
- Pharmaceutical companies using drug delivery and research-related products
- Public health agencies and nonprofit providers using prevention and testing products
- Consumers and retail pharmacies for selected home and retail channels

## Geography

BD sells products worldwide and organizes operations outside the United States across Europe, META, Greater Asia, Latin America, and Canada. The company disclosed that 2025 revenue was $12.79 billion in the United States and $9.05 billion internationally, meaning the U.S. remains the largest single market but international sales are nearly as important. International exposure is broad, with Greater Asia including China, Japan, South Asia, Southeast Asia, Korea, Australia, and New Zealand, while Latin America includes Mexico, Central America, the Caribbean, and South America. BD also highlighted emerging markets such as Eastern Europe, the Middle East and Africa, Latin America, and parts of Greater Asia as growth priorities. Geography matters because local procurement rules, reimbursement systems, currency swings, and government healthcare policies can materially affect demand and pricing, especially in China and other emerging markets.

- **United States** (58.5%)
- **International** (41.5%) — Includes Europe, META, Greater Asia, Latin America, and Canada.

- United States is the largest revenue market and a key driver of growth
- International sales are substantial and diversified across multiple regions
- Europe and META are managed separately in the new operating structure
- Greater Asia includes China, Japan, South Asia, Southeast Asia, Korea, ANZ
- Latin America includes Mexico, Central America, the Caribbean, and South America
- Canada is separately managed outside the U.S. in the regional structure
- Emerging markets are a stated growth focus but carry policy and pricing risk

## Strategy

BD’s stated strategy is anchored in three pillars: grow, simplify, and empower. On the growth side, the company is investing in smart devices, robotics, analytics, artificial intelligence, R&D, and tuck-in acquisitions to extend category leadership and expand into faster-growing markets. Simplification focuses on BD Excellence, factory productivity, portfolio rationalization, and operating-model changes intended to improve margins and customer experience. The company is also emphasizing quality management, digitalization, and global scale to support reliable supply and broader access to affordable medical technologies. The planned separation of the Biosciences and Diagnostic Solutions business with Waters is a major portfolio action that should sharpen the remaining company’s focus on core medical technology franchises.

- **Accelerate innovation in connected and intelligent medical technologies** (medium-term) — BD wants to defend and extend its position in regulated care workflows by adding automation, analytics, and AI that improve outcomes and lower costs.
- **Simplify the operating model and improve productivity** (short-term) — Reducing complexity and improving factory efficiency should support margin expansion and better service levels in a competitive market.
- **Rebalance the portfolio through separation and acquisitions** (medium-term) — The Waters transaction and tuck-in acquisitions are intended to sharpen focus on core franchises and add growth in attractive niches.

- Invest in smart devices, robotics, analytics, and AI to improve care workflows
- Use R&D to strengthen core product leadership and build the pipeline
- Pursue tuck-in acquisitions in faster-growing market segments
- Expand globally, including under-resourced and emerging markets
- Drive productivity through BD Excellence and manufacturing efficiency
- Simplify the portfolio and operating model to reduce complexity
- Improve customer experience through digitalized internal and go-to-market processes
- Separate the Biosciences and Diagnostic Solutions business with Waters

## Risks

BD faces a mix of company-specific execution risks and broad medtech industry risks. The company highlighted pressure from China volume-based procurement, compliance enforcement, and weaker government research funding, all of which can reduce volumes or delay customer purchases. As a global medical device manufacturer, BD is also exposed to inflation, supply chain disruption, tariffs, currency volatility, and higher interest rates, which can affect both demand and cost structure. Product quality, recalls, regulatory actions, and cybersecurity incidents are especially important because BD’s products are used in patient care and any defect can trigger liability, remediation costs, and reputational damage. Competition is intense across diagnostics, safety-engineered devices, and life sciences, with pricing pressure from low-cost manufacturers and specialized rivals.

- **China market dynamics and volume-based procurement** [high] — BD explicitly said China VoBP and compliance enforcement have adversely affected and may continue to affect results by lowering volumes and pricing.
- **Product quality failures and recalls** [high] — Medical device defects can lead to recalls, regulatory actions, product liability claims, and lost sales in patient-critical settings.
- **Supply chain disruption and inflation** [medium] — BD relies on global manufacturing and distribution, so inflation, logistics issues, and component shortages can raise costs and impair service levels.
- **Cybersecurity and product tampering** [high] — A breach or tampering event could affect device functionality, patient safety, privacy compliance, and customer trust.
- **Government research funding and capital spending weakness** [medium] — Reduced funding or higher interest rates can delay purchases of laboratory and capital equipment, especially in Life Sciences and diagnostics.

- China procurement and compliance actions can pressure volumes and pricing
- Government research funding cuts can delay purchases of instruments and diagnostics
- Inflation, tariffs, and supply chain disruptions can raise costs and disrupt supply
- Currency volatility affects reported results and cash flows from international sales
- Product defects or recalls can create liability, remediation, and reputational damage
- Cybersecurity incidents could affect product functionality, data integrity, and compliance
- Competitive pricing pressure is high in safety devices, diagnostics, and life sciences

## Accounting

BD’s revenue recognition is judgmental because gross revenue is reduced by rebates and other deductions that depend on estimates of distributor inventory, sell-through timing, and payment lags. This means reported revenue can move differently from underlying shipment activity when rebate assumptions change. The company also has meaningful seasonality in certain medical devices and flu diagnostic products, which can create quarter-to-quarter volatility and make interim comparisons less representative of full-year demand. Goodwill and intangible assets are another critical area because BD operates through multiple reporting units and must test goodwill annually; any deterioration in market conditions or expected cash flows could trigger impairment charges. Acquisition accounting also matters because recent deals can create inventory step-up adjustments, amortization expense, and remediation or legal reserves that affect gross margin and operating profit.

- **Revenue deductions and rebate accruals** — Can shift revenue and margins between periods
- **Goodwill and intangible asset impairment** — Potential non-cash write-downs
- **Acquisition accounting and purchase price adjustments** — Affects cost of products sold and amortization
- **Product remediation and legal reserves** — Affects cost of products sold and other operating expense

- Revenue deductions and rebates require estimates that affect net sales timing
- Distributor inventory assumptions can shift revenue recognition and rebate accruals
- Seasonality in some devices and flu diagnostics affects quarterly comparability
- Goodwill impairment testing is important across multiple reporting units
- Finite-lived intangibles and developed technology create ongoing amortization
- Acquisition accounting can add inventory step-up and fair value adjustments
- Product remediation and legal reserves can change cost of sales and operating expense

---

*Last updated: 2026-09-24T12:11:04.374221+00:00*